Investors are excited (perhaps a little too excited) about a new opportunity in immuno-oncology.
The genetic testing leader continues to set new quarterly revenue records.
Gene therapies, here we come.
China's biopharma gem drifted lower in the first half of 2019, but there's no identifiable explanation or cause for concern.
Wall Street admitted that it may have overreacted last year.
Investors were all too happy to reward the business for its hasty progress on an operating efficiency program.
The bioprocess engineering leader continued to deliver spectacular growth and bolster its profitability.
These businesses are likely to be better than ever two decades from now.
Stubborn headwinds in the generic-drug markets are forcing the company to restructure operations.
The field expanded into a new therapeutic area, and fell back into a bitter dispute over intellectual property.
The post-IPO blues hit pretty hard last month.
The good news keeps rolling in for this Belgian pharma.
Was last month a turning point in a not-so-good year for shareholders?
The company rebounded after remedying an embarrassing regulatory gaffe.
The clinical-stage biopharma announced promising data at a major conference.
The pharmaceutical pipeline shined, and the business doubled its cash position.
The business reported an upbeat update, but something got lost in translation on Wall Street.
The immune cells live up to their name in natural settings, but engineered therapies have delivered mixed results in clinical trials.
These businesses are turning wasteful consumption into long-term value for shareholders and the planet.
Wall Street might be overlooking these intriguing investing opportunities.